|
|
Post by otherottawaguy on May 9, 2018 8:51:50 GMT -5
Anyone care to offer their ed-u-ma-cated opinion?
Current opinion (can't call it a consensus as its only):
Earnings announcement* for MNKD: May 09, 2018
MannKind Corporation is expected* to report earnings on 05/09/2018 after market close. The report will be for the fiscal Quarter ending Mar 2018. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.22.
Last four quarters:
Quarterly Earnings Surprise History
Fiscal
Quarter, End Date
, Reported Earnings
Per Share, Consensus
EPS*, Forecast %
Surprise
Dec2017 02/27/2018 -0.28 -0.29 3.45
Sep2017 11/07/2017 -0.31 -0.27 -14.81
Jun2017 08/07/2017 -0.35 -0.25 -40
Mar2017 05/10/2017 -0.22 -0.09 -144.44
|
|
|
|
Post by peppy on May 9, 2018 9:39:33 GMT -5
quote "Anyone care to offer their ed-u-ma-cated opinion?
Current opinion (can't call it a consensus as its only): "
Upon deep consideration, and because no one rushed to answer, my current consensus opinion is bend over.
|
|
|
|
Post by traderdennis on May 9, 2018 9:46:33 GMT -5
Anyone care to offer their ed-u-ma-cated opinion? Current opinion (can't call it a consensus as its only):
Earnings announcement* for MNKD: May 09, 2018
MannKind Corporation is expected* to report earnings on 05/09/2018 after market close. The report will be for the fiscal Quarter ending Mar 2018. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.22. Last four quarters:Quarterly Earnings Surprise History
Fiscal Quarter, End Date , Reported Earnings Per Share, Consensus EPS*, Forecast % Surprise Dec2017 02/27/2018 -0.28 -0.29 3.45 Sep2017 11/07/2017 -0.31 -0.27 -14.81 Jun2017 08/07/2017 -0.35 -0.25 -40 Mar2017 05/10/2017 -0.22 -0.09 -144.44 As long as expenses are kept inline the eps should improve because share count has risen due to Deerfield and amphastar payments in dilution. Further improvement in q2 with the pipe offering. |
|
|
|
Post by babaoriley on May 9, 2018 11:09:28 GMT -5
TD, you do have a point! I give you credit for coming up with that, nicely done!
|
|
bac
Lab Rat
Posts: 37
|
Post by bac on May 9, 2018 13:08:38 GMT -5
The year ago EPS were influenced by the Sanofi settlement. If you neglect that, and linearly extend the last three EPS values (-$0.35, -$0.31, -$0.28), you get about -$0.25 loss per share for Q1 2018.
Tracking EPS from quarterly CC could enable one to very simply predict when MNKD will break-even.
Any other ways to predict break-even?
|
|
|
|
Post by Omega on May 9, 2018 13:17:47 GMT -5
The year ago EPS were influenced by the Sanofi settlement. If you neglect that, and linearly extend the last three EPS values (-$0.35, -$0.31, -$0.28), you get about -$0.25 loss per share for Q1 2018. Tracking EPS from quarterly CC could enable one to very simply predict when MNKD will break-even. Any other ways to predict break-even? That will show you a trend line to break even. But doesn't count a lot of outside factors. Doesn't consider any future higher rate of spending with DTC. It assumes the same steady increase in scripts and no hockey stick increase ever. Also with increased sales our cost per unit goes down due to some of the fixed costs we already have in place such as the plant. That's just off the top of my head. |
|
